Tocolytic Therapy in Preterm Premature Rupture of Membranes

Obstet Gynecol Clin North Am. 2020 Dec;47(4):569-586. doi: 10.1016/j.ogc.2020.08.003. Epub 2020 Oct 7.

Abstract

"Trials evaluating tocolytic use in preterm premature rupture of membranes (PPROM) have been small and lacked adequate power to evaluate uncommon outcomes. There still is much controversy on the benefit, length of use, route, and drug of choice among clinicians treating patients with PPROM. Most professional medical societies would propose to consider the use of tocolytics for 48 hours to allow for corticosteroid administration or to allow for maternal transfer to a higher level of care. Longer treatment regimens may lead to adverse maternal and perinatal outcomes. Insufficient data are available to make stronger and more definitive recommendations."

Keywords: Membranes; Preterm; Rupture; Tocolysis; Tocolysis for PPROM.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Female
  • Fetal Membranes, Premature Rupture / drug therapy*
  • Humans
  • Infant, Newborn
  • Magnesium Sulfate / therapeutic use
  • Pregnancy
  • Premature Birth / prevention & control
  • Ritodrine / therapeutic use
  • Tocolysis / methods
  • Tocolytic Agents / therapeutic use*

Substances

  • Adrenal Cortex Hormones
  • Tocolytic Agents
  • Magnesium Sulfate
  • Ritodrine

Supplementary concepts

  • Preterm Premature Rupture of the Membranes